News

August 5, 2020August 5, 2020

Isturisa Leads to Rapid, Sustained Reduction in Cortisol Levels, Data Show

News

Treatment with Isturisa (osilodrostat) led to a rapid and sustained reduction in cortisol levels and was well-tolerated in people with Cushing’s disease, according to newly published data from the ... Read more

July 29, 2020July 29, 2020

Phase 3 Relacorilant Trial Enrolling Cushing’s Patients With Adrenal Origin

News

The first patient has been enrolled in Corcept Therapeutics‘ Phase 3 GRADIENT trial, which is evaluating relacorilant as a potential treatment for people with Cushing’s syndrome due to either ... Read more

July 24, 2020August 6, 2020

Ketoconazole May Be Better Choice for Cushing’s Syndrome Patients When Surgery Is Not Available

News

Note: This story was updated Aug. 6, 2020, to note that ketoconazole is approved to treat Cushing’s in Europe and is used off-label for the same indication in the ... Read more

July 22, 2020July 22, 2020

Isturisa, Oral Treatment for Cushing’s Syndrome, Available in Germany

News

Isturisa (osilodrostat) is now available in Germany to treat adults with endogenous Cushing’s syndrome. The announcement by Recordati Rare Diseases, which acquired rights to Isturisa from its original developer Novartis, follows ... Read more

July 17, 2020July 17, 2020

Smart Contact Lens Shows Ability to Measure Cortisol Levels

News

A newly developed smart contact lens might be used to measure levels of the hormone cortisol in a person’s tears, which could be helpful in disorders such as Cushing’s disease. ... Read more

July 15, 2020July 15, 2020

Estrogen Receptor Alpha May Be Involved in Development of Cushing’s During Pregnancy

News

Estrogen receptor alpha — one of the two main types of protein receptors activated by the female sex hormone estrogen — likely is involved in the development of Cushing’s ... Read more

July 10, 2020July 10, 2020

Last Patient Completes Withdrawal Phase of Recorlev Trial for Cushing’s

News

The last patient has completed the last study visit in the withdrawal phase of the Phase 3 LOGICS clinical trial that is investigating the safety and effectiveness of Recorlev (levoketoconazole) ... Read more

July 10, 2020July 10, 2020

National Survey Seeks to Assess Full Social, Economic Burdens of Rare Diseases in US

News, syndicated

The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease ... Read more

July 8, 2020July 8, 2020

Adrenal Cushing’s Syndrome More Common in Southeast Asia, Study Finds

News

The proportion of Cushing’s syndrome patients whose disease is caused by a tumor in the adrenal glands is higher in Asia than in other continents. Now, researchers in Thailand ... Read more

July 1, 2020July 1, 2020

Isturisa Effective in Treating Cushing’s Syndrome Other Than Cushing’s Disease, Phase 2 Trial Shows

News

Recordati’s Isturisa (osilodrostat) safely and effectively normalizes urinary levels of cortisol in people with endogenous Cushing’s syndrome other than Cushing’s disease, according to data from a Phase 2 clinical ... Read more

Pin It on Pinterest